|
Market Closed -
Nasdaq
16:00:00 2026-11-09 EST
|
5-day change | 1st Jan Change | ||
| 0.8923 USD | +7.51% |
|
-11.18% | -77.41% |
Company Valuation: BioNexus Gene Lab Corp.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 236.3 | 364.7 | 165 | 9.364 | 5.026 | 9.337 |
| Change | - | 54.35% | -54.75% | -94.33% | -46.33% | 85.79% |
| Enterprise Value (EV) 1 | 233.6 | 362.6 | 163 | 3.581 | 0.8759 | 5.523 |
| Change | - | 55.23% | -55.06% | -97.8% | -75.54% | 530.58% |
| P/E | 216x | 485x | -461x | -3.2x | -3.12x | -2.46x |
| PBR | 59.1x | 50.8x | 24.8x | 0.97x | 0.6x | 1.11x |
| PEG | - | -8.3x | 3x | -0x | 0.1x | -0x |
| Capitalization / Revenue | 20.7x | 27.3x | 15.1x | 0.96x | 0.53x | 1.26x |
| EV / Revenue | 20.5x | 27.1x | 14.9x | 0.37x | 0.09x | 0.74x |
| EV / EBITDA | 355x | 316x | -816x | -1.83x | -0.49x | -1.85x |
| EV / EBIT | 412x | 343x | -560x | -1.75x | -0.46x | -1.78x |
| EV / FCF | -127x | -3,300x | 239x | 6.32x | -0.46x | -6.5x |
| FCF Yield | -0.79% | -0.03% | 0.42% | 15.8% | -218% | -15.4% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 1.276 | 0.5267 | -0.247 | -1.656 | -0.897 | -1.607 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 11.39 | 13.36 | 10.93 | 9.771 | 9.511 | 7.425 |
| EBITDA 1 | 0.6577 | 1.147 | -0.1998 | -1.959 | -1.793 | -2.987 |
| EBIT 1 | 0.5669 | 1.056 | -0.2912 | -2.042 | -1.897 | -3.099 |
| Net income 1 | 1.094 | 0.7516 | -0.356 | -2.629 | -1.598 | -2.985 |
| Net Debt 1 | -2.664 | -2.047 | -2.062 | -5.783 | -4.15 | -3.814 |
| Reference price 2 | 276.0001 | 255.6001 | 114.0000 | 5.3000 | 2.7970 | 3.9500 |
| Nbr of stocks (in thousands) | 856 | 1,427 | 1,448 | 1,767 | 1,797 | 2,364 |
| Announcement Date | 3/30/21 | 4/6/22 | 3/31/23 | 4/16/24 | 4/15/25 | 4/14/26 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 2.43M | |
| 17.43x | 6.68x | 12.81x | 1.71% | 66.7B | |
| 30.07x | 8.27x | 26.77x | 0.07% | 56.88B | |
| 38.45x | 6.84x | 20.45x | 0.85% | 56.53B | |
| 46.55x | 6.14x | 30.16x | -.--% | 46.49B | |
| 35.48x | 3.35x | 14.48x | -.--% | 44.8B | |
| -22.71x | 62.58x | -21.48x | -.--% | 41.59B | |
| 35.87x | 8.84x | 23.03x | 0.37% | 35.35B | |
| 41.46x | 8.08x | 26.8x | -.--% | 33.29B | |
| -69.81x | 13.21x | -71.01x | -.--% | 25.1B | |
| Average | 16.98x | 13.78x | 6.89x | 0.33% | 41B | |
| Weighted average by Cap. | 21.52x | 12.92x | 11.34x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- BGLC Stock
- Valuation BioNexus Gene Lab Corp.
Select your edition
All financial news and data tailored to specific country editions
